Allosteric equilibria of thrombin and its precursors

Information

  • Research Project
  • 10168600
  • ApplicationId
    10168600
  • Core Project Number
    R01HL147821
  • Full Project Number
    5R01HL147821-03
  • Serial Number
    147821
  • FOA Number
    PA-18-484
  • Sub Project Id
  • Project Start Date
    6/1/2019 - 5 years ago
  • Project End Date
    5/31/2023 - a year ago
  • Program Officer Name
    KINDZELSKI, ANDREI L
  • Budget Start Date
    6/1/2021 - 3 years ago
  • Budget End Date
    5/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
  • Award Notice Date
    6/14/2021 - 3 years ago
Organizations

Allosteric equilibria of thrombin and its precursors

The proposed research project focuses a recently uncovered, paradigm-shifting structure-function link relevant to the entire family of trypsin-like enzymes to which thrombin belongs. A pre-existing, allosteric equilibrium between ensembles of closed (E*) and open (E) conformations of the active site influences the level of activity and mechanism of binding in the protease. The equilibrium also exists in the zymogen and explains the spontaneous autoactivation observed with several proteins involved in blood coagulation, immune response, fibrinolysis and development. Observational evidence of the E*-E equilibrium comes from a large body of structures currently deposited in the Protein Data Bank. Additional independent evidence comes from rapid kinetics measurements of ligand binding to the active site of protease and zymogen that support conformational selection as a general mechanism of recognition in the trypsin fold. Studies under specific aim 1 will test the hypothesis that protease and zymogen undergo the E*-E equilibrium in solution and that the relative distribution of E* and E influences activity in the protease and the mechanism of activation in the zymogen. A significant component of these studies will involve pioneering NMR (2D and 19F) measurements of thrombin and prethrombin-2 with the goal of elucidating, for the first time, the structure and dynamics of their free conformation(s) in solution. We will focus on the likely structural determinants of the E*-E equilibrium and critical residues that decorate the entrance to the active site region in the 215-217 segment (W215, G216, E217), the 60-loop (W60d), the autolysis loop (W148) and the 190-193 corridor (E192). The functional role of these residues will be tested by rapid kinetics measurements of ligand binding to the active site of wild-type and mutants of thrombin and its direct zymogen precursor prethrombin-2. These studies will advance our understanding of a basic structure-function link of the trypsin fold and will provide background for studies to be carried out under specific aim 2. Members of the trypsin family of proteases, to which thrombin belongs, are expressed as inactive zymogens and irreversibly converted to the mature protease by proteolytic cleavage at R15 in the activation domain. The cleavage generates a new N-terminus that inserts into the protein core and H-bonds to the side chain of residue D194. Elucidating how the Huber-Bode mechanism of zymogen activation described above is linked to the allosteric E*-E equilibrium will be center stage in our investigation. We will perturb the critical I16- D194 H-bond with several substitutions that weaken or abolish the interaction. Each mutant will be studied by rapid kinetics to directly measure the E*-E distribution in solution. Additionally, key mutants such as D914A will be characterized structurally for the first time by X-ray and NMR to complement studies of prethrombin-2 and thrombin under specific aim 1. Developments from this specific aim will elucidate the linkage between two critical features of the trypsin fold, i.e., the allosteric E*-E equilibrium and the Huber-Bode mechanism, in ways that will advance our basic knowledge of one the largest families of proteases.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
    250000
  • Indirect Cost Amount
    128750
  • Total Cost
    378750
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    839
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NHLBI:378750\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    HT
  • Study Section Name
    Hemostasis and Thrombosis Study Section. Committee was terminated on 11/30/2020.
  • Organization Name
    SAINT LOUIS UNIVERSITY
  • Organization Department
    BIOCHEMISTRY
  • Organization DUNS
    050220722
  • Organization City
    SAINT LOUIS
  • Organization State
    MO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    631032006
  • Organization District
    UNITED STATES